On Monday, Agios Pharmaceuticals Inc (NASDAQ: AGIO) was 9.56% up from the session before settling in for the closing price of $38.97. A 52-week range for AGIO has been $20.96 – $62.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 2.66% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 281.41%. With a float of $55.14 million, this company’s outstanding shares have now reached $57.02 million.
In an organization with 383 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 76.16%, operating margin of -1238.1%, and the pretax margin is 2212.98%.
Agios Pharmaceuticals Inc (AGIO) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Agios Pharmaceuticals Inc stocks. The insider ownership of Agios Pharmaceuticals Inc is 3.32%, while institutional ownership is 104.72%. The most recent insider transaction that took place on Dec 11 ’24, was worth 9,256. In this transaction Director of this company sold 200 shares at a rate of $46.28, taking the stock ownership to the 15,483 shares. Before that another transaction happened on Nov 08 ’24, when Company’s Principal Accounting Officer sold 772 for $56.09, making the entire transaction worth $43,301. This insider now owns 813 shares in total.
Agios Pharmaceuticals Inc (AGIO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 281.41% per share during the next fiscal year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
You can see what Agios Pharmaceuticals Inc (AGIO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 75.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 11.37, a number that is poised to hit -1.68 in the next quarter and is forecasted to reach -6.13 in one year’s time.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
Let’s dig in a bit further. During the last 5-days, its volume was 1.57 million. That was better than the volume of 0.72 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 9.90%. Additionally, its Average True Range was 3.88.
During the past 100 days, Agios Pharmaceuticals Inc’s (AGIO) raw stochastic average was set at 21.63%, which indicates a significant decrease from 21.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 122.64% in the past 14 days, which was higher than the 62.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $49.70, while its 200-day Moving Average is $42.03. However, in the short run, Agios Pharmaceuticals Inc’s stock first resistance to watch stands at $45.22. Second resistance stands at $47.76. The third major resistance level sits at $51.05. If the price goes on to break the first support level at $39.39, it is likely to go to the next support level at $36.10. Assuming the price breaks the second support level, the third support level stands at $33.56.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Key Stats
There are 57,030K outstanding shares of the company, which has a market capitalization of 2.49 billion. As of now, sales total 26,820 K while income totals -352,090 K. Its latest quarter income was 8,960 K while its last quarter net income were 947,920 K.
